M&A Material Adverse Effect (MAE) Screener

The Burden of Proving a Material Adverse Effect in Delaware M&A

In transaction dispute litigation, seeking to walk away from a signed merger agreement or acquisition contract is one of the most high-stakes corporate decisions. In Delaware (under whose laws a majority of public US companies are incorporated), the courts allocate a heavy burden of proof to the acquirer seeking to establish a Material Adverse Effect (MAE) or Material Adverse Change (MAC).

This calculator models the strict quantitative and qualitative factors defined by the Delaware Court of Chancery across decades of landmark case law, including IBP v. Tyson Foods (2001), Hexion v. Huntsman (2008), and Akorn v. Fresenius (2018).

1. Quantitative Magnitude: EBITDA as the Standard Yardstick

While merger agreements are signed on enterprise and equity values, Delaware courts look primarily at the target's operating earnings capacity rather than temporary stock market price fluctuations. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) over a trailing twelve-month (LTM) period serves as the primary metric.

To qualify as an MAE, a financial drop must be massive. In Akorn, the court upheld termination where EBITDA collapsed by over 80%. Historically, drops of less than 20% to 30% are viewed by the Court of Chancery as standard business volatility rather than structural collapses of enterprise value.

2. Durational Significance: Measured in Years, Not Months

A fundamental requirement established in IBP v. Tyson Foods is the concept of durational significance. A short-term drop, even if severe (such as a 64% first-quarter earnings decline), is insufficient to trigger an MAE if the business is expected to recover in the medium term.

• Short-Term / Cyclical: Fluctuations lasting under 6 months are generally treated as systemic or seasonal, which do not impair long-term strategic value.
• Long-Term / Structural: An MAE requires a structural impairment that alters the target's long-term earnings potential, which courts expect to be measured in years rather than months.

3. Risk Allocation: Exclusions, Carve-Outs, and Disproportionality

Modern merger agreements are sophisticated risk-allocation contracts. They contain standard "carve-outs"—risks that the buyer explicitly agrees to bear. These standard carve-outs include:

• General economic downturns, changes in interest rates, or inflation.
• General downturns across the target's specific industry.
• Changes in underlying laws, regulations, tax codes, or accounting standards (GAAP).
• Natural disasters, pandemics, acts of war, or terrorism.

However, these carve-outs are almost always subject to a "Disproportionate Impact Exception." If a general industry crisis or inflation hit the target company disproportionately harder than its direct industry competitors, the carve-out is overridden. The buyer can then claim an MAE. This calculator computes the exact "Disproportionality Margin" to assess whether this exception has been triggered.

4. Buyer's Remorse vs. Prior Knowledge

Courts look extremely closely at the buyer's internal files and conduct. Under the Channel Medsystems standard, if a buyer seeks to manufacture an MAE as a pretext to renegotiate a price or escape a deal they simply no longer like (classic "buyer's remorse"), the court will heavily discount the buyer's claims. Furthermore, if a specific risk or problem (like a known FDA investigation or patent expiry) was fully disclosed to the buyer before signing, the buyer cannot later use that specific issue to claim an unexpected MAE.

Summary of Key Judicial Precedents